CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (NCT05722418)
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- CU Anschutz Medical Campus, Anshutz Cancer Pavillion — Aurora, Colorado
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics — Miami, Florida
- University of Kentucky/ Markey Cancer Center — Lexington, Kentucky
- Hackensack Meridian John Theurer Cancer Center — Hackensack, New Jersey
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Duke University Health System (DUHS) — Durham, North Carolina
- Oncology Hematology Care, Inc — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Tennessee Oncology — Nashville, Tennessee
- University of Texas Southwestern Medical Center — Dallas, Texas
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- Virginia Commonwealth University — Richmond, Virginia
- Froedtert and the Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (510) 982-6030
Email: clinicaltrials@cariboubio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed/Refractory Multiple Myeloma
- A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets — Stanford, California
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma — Little Rock, Arkansas
- Cevostamab Following CAR T Cell Therapy for RRMM — Philadelphia, Pennsylvania
- A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma — Clayton, North Carolina
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Relapsed/Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.